BAGSVAERD, Denmark — Lars Fruergaard Jorgensen has a problem: Too many people want what he’s selling. Jorgensen is CEO of Novo Nordisk, a Danish drugmaker. Even if the company isn’t quite a household name, the TV jingle for its bestselling drug — “Oh-oh-ohhh-Ozempic!” — might ring in your ears. Across the United States, Novo Nordisk’s diabetes and weight-loss drugs, Ozempic and Wegovy, have soared to celebrity status and helped make the company Europe’s most valuable public firm. It can’t make e